A Medical Device Daily
BioElectronics (Frederick, Maryland) reported an agreement to expand with Tecnica Scientifica Service Medical (TSS; Torino, Italy) its medical provider distributor into Italy's retail pharmacies. TSS Medical has acquired 10,000 units to initiate the retail product launch.
"TSS Medical had an exceptional response to the ActiPatch products, both at the ESRA Congress in Salerno and at the Congress of Chronic Pain in Genoa. Our sales representatives have reported an extremely positive response to ActiPatch. We are very excited about the market potential for this innovative, drug-free therapy. We are eager to introduce ActiPatch to the retail consumers in Italy. We expect to exceed the minimum annual purchase requirements of the contract and look forward to many successful years of business with BioElectronics," said Alessio Petricca, head of marketing and operations of TSS Medical.
"We are confident that TSS Medical will play a major role in expanding the use of ActiPatch in Italy. We are pleased to have them launching our exceptional line of retail drug free anti-inflammatory products in the European Common Market," said Kelly Lorenz of BioElectronics.
TSS distributes medications and medical devices for postoperative recovery and chronic pain.
BioElectronics is the maker of ActiPatch a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day.
In other agreements:
- Digirad (Poway, California) a provider of medical diagnostic imaging systems and services to physicians' offices, hospitals and imaging centers, reported the signing of a letter of agreement with the Methodist Hospital in Houston (Methodist). The fifth since the inception six months ago of Digirad's centers of influence business strategy, Digirad and Methodist will provide imaging and reading services, respectively, to primary-care physicians in the Houston area who are seeking to expand their practices with in-office imaging. Through its mobile imaging operations, Digirad will bring state-of-the-art equipment and qualified, trained personnel into physicians' offices to perform the imaging. The patients' images will be interpreted by Methodist physicians and the results sent electronically to the referring physician. Digirad provides diagnostic medical imaging systems and services to physicians' offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications.
- Health Language (HLI; Aurora, Colorado) a supplier of language engine technology for medical vocabulary, reported that ActiveHealth Management (New York) a clinically-based, technology-driven health management services company, has selected HLI to deliver administrative and clinical content management tools. The HLI Language Engine provides a tool for payers, healthcare organizations, IT vendors and government agencies to effectively localize, update and disseminate over 70 controlled, licensed healthcare terminologies, mappings and other terminology-related content issued by a growing number of standards bodies. Standardized medical terminology has been identified as a critical element to ensuring advanced interoperability among various healthcare IT applications; thus, contributing to improved patient safety, superior clinician decision-making capabilities and rapid reimbursement. HLI provides software and services solutions that support recurring updates and management of codes sets and medical terminology on a scheduled basis. Additionally, Health Language's technology supplies functionality to deliver consumer terminology content and maps between code sets to support advanced initiatives in care management, CMS medical payment policy edits, P4P, and normalization of disparate databases. This mapping capability delivers the foundation for future migration from ICD-9 CM to ICD-10 CM. Furthermore, the extensive HLI library of APIs allows clients such as ActiveHealth Management to integrate HLI Language Engine capabilities into corporate applications using .NET, JAVA, EJB and Microsoft client architectures.
- Anika Therapeutics (Bedford, Massachusetts) reported that it and Galderma Pharma and Galderma (both Paris) have closed on their agreement to terminate all license, development and supply arrangements among the companies for the Elevess family of products. Anika has now reacquired the worldwide rights to the future development and marketing of Elevess, including ownership of the "Elevess" trademark, and all related packaging, marketing and promotional materials, as well as the clinical studies, marketing research and training materials developed by Galderma. "We have begun moving forward in the search for a new partner for Elevess," said Gregory Fulton, VP of Marketing, Aesthetics and Ophthalmics. "There has been considerable interest expressed already by new potential partners, and we are actively pursuing these opportunities. In addition, we are continuing with pre-launch activities, which include reaching out to key opinion leaders. We plan to launch Elevess in the first half of next year and are confident that we will execute on our strategy to make dermal fillers an important franchise for the company." Elevess is the first injectable soft-tissue filler for facial wrinkles, scar remediation and lip augmentation to incorporate lidocaine, a local anesthetic that improves patient comfort and satisfaction and provides physicians with a new alternative for their aesthetic practice. Anika develops therapeutic products for tissue protection, healing and repair.